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Serum lipids status in patients with diabetic uremia on 10 years reporting the dyslipidemia in the diabetic uremia on
of maintenance hemodialysis. long-term hemodialysis treatment [1, 2].
Background. Dyslipidemia in patients with diabetic uremic The principal features of the impaired lipid metabo-patients remains unclear. We previously reported that lipid
lism in nondiabetic uremic subjects include the increaseabnormalities in diabetic uremia on short-term (3 to 28 months)
in the very low-density lipoprotein (VLDL) and interme-hemodialysis therapy were more severe than those in nondia-
betic uremic patients. The object of this study is to investigate diate-density lipoprotein (IDL) fractions, which are
the serum lipid profiles in diabetic uremic patients on 10 years mainly due to a defect in the catabolism of triglyceride-
of maintenance hemodialysis treatment. rich lipoproteins [3] and the decrease in the high-density
Methods. Thirty diabetic uremic subjects and 40 age-matched
lipoprotein (HDL) fraction [3, 4]. In contrast, diabeticnondiabetic subjects on long-term hemodialysis therapy were
lipid abnormalities in the absence of renal insufficiencyselected, and their clinical characteristics and serum concentra-
tions of lipids, apolipoproteins, lecithin cholesterol acyltrans- are reported as hypertriglycemia, with a decreased con-
ferase (LCAT) activity, and apolipoprotein (apo) E phenotype centration of HDL and an elevated level of VLDL, which
were evaluated. is mainly due to an increase in VLDL-triglyceride syn-
Results. Patients with diabetic uremia had a higher preva- thesis [5, 6].lence of macrovascular complications, including ischemic heart
In this study, we investigated serum lipid status indiseases and cerebrovascular diseases. The mean levels of se-
diabetic uremic patients undergoing long-term hemodi-rum total cholesterol, triglyceride, and high-density lipoprotein
cholesterol remained normal. Nondiabetic uremic patients ex- alysis treatment (over 10 years) compared with those
hibited a reduction in serum apo A-1, serum apo A-2, serum nondiabetic long-term survivors. Furthermore, the apoli-
apo C-2, and LCAT activity and an increase in serum Apo poprotein (apo) E phenotype was also examined to in-
C-3. Diabetic uremic patients showed a further reduction in
vestigate apo E isoform-dependent effects on the etiol-serum apo A-1, serum apo A-2, serum apo E, and LCAT
ogy of dyslipidemia in patients with diabetic renal failureactivity. Frequencies of apo E isoforms were not significantly
on long-term hemodialysis treatment.different between two groups of uremic patients.
Conclusions. These results clearly indicate that lipid abnor-
malities in diabetic uremic patients on long-term hemodialysis
METHODStherapy are more enhanced than those in nondiabetic uremic
patients, suggesting that diabetic hemodialyzed patients are more Patients
prone to increase the individual risk for accelerated atheroscle-
Thirty diabetic uremic subjects and 40 age-matchedrosis to cause a higher incidence of cardiovascular diseases.
nondiabetic subjects were reviewed in a survey of dialysis
patients conducted by the Hyogo Society for Dialysis
Therapy (Table 1). The mean duration of hemodialysisAtherosclerosis and cardiovascular disturbance are
therapy was 14.4 and 14.8 years in diabetic and nondia-common among hemodialysis subjects, particularly in
betic patients, respectively. All diabetic patients had typepatients with diabetic uremia. Although the cause is prob-
2 (non–insulin-dependent) diabetes mellitus, and renalably multifactorial, the dyslipidemia associated with dia-
insufficiency in nondiabetic patients was most commonlybetic renal insufficiency appears to be a major risk factor
due to glomerulonephritis and polycystic kidney.for atherosclerosis. However, there are not any studies
Analysis of serum concentrations of lipids and
apolipoproteins and apolipoprotein E phenotypingKey words: APO E allele, apolipoprotein, LCAT, lipid abnormalities,
long-term hemodialysis. Blood samples were collected in the morning of dial-
ysis immediately before the start of the session. The 1999 by the International Society of Nephrology
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Table 2. Serum concentrations of lipids, apoproteins, LCATTable 1. Clinical characteristics of diabetic (DM) and nondiabetic
(Non-DM) uremic patients on 10 years of activity, and apoprotein E phenotyping of diabetic (DM)
and nondiabetic (Non-DM) uremic patientsmaintenance hemodialysis
Non-DM DM P value Non-DM DM P value
Serum lipids and apolipoproteinsClinical profiles
Number (M/F) 40 (20/20) 30 (15/15) Total cholesterol mg/dl 174.8638.2 164.5643.7 NS
Triglyceride mg/dl 120.0671.9 144.9666.6 NSAge years 60.968.7 62.5 68.0 NS
Body mass index kg/m2 20.463.0 19.2 62.2 NS HDL-cholesterol mg/dl 50.2616.1 44.7617.6 NS
LDL-cholesterol mg/dl 100.6627.9 85.2628.8 NSSerum albumin g/dl 3.7160.34 3.69 60.3 NS
Fasting blood sugar mg/dl — 150.469.6 Apolipoprotein A-1 mg/dl 110.6621.7 95.1619.6 ,0.01
Apolipoprotein A-2 mg/dl 20.765.1 17.265.2 ,0.03Serum creatinine mg/dl 11.562.1 11.4 62.5 NS
Serum urea-N mg/dl 69.1613.2 74.1 616.2 NS Apolipoprotein B mg/dl 88.2620.8 77.0617.8 ,0.05
Apolipoprotein C-2 mg/dl 3.0961.8 2.3861.5 NSPrevalence of vascular complications
Ischemic heart disease % 7.861.0 13.362.6 ,0.05 Apolipoprotein C-3 mg/dl 11.563.5 10.363.5 NS
Apolipoprotein E mg/dl 3.8560.9 3.1160.9 ,0.005Cerebrovascular disease % 3.861.4 13.361.9 ,0.01
Gangrene in lower extremities % 0.6760.09 10.2 61.3 ,0.001 LCAT activity U/dl 48.4622.6 29.8617.7 ,0.003
Apolipoprotein E phenotypingNon-paired Student’s t-test was used to determine P values. All values are
Apo E4/4 % 0 5.5660.2 NSgiven as the mean 6 standard deviation.
Apo E4/3 % 12.260.3 16.760.4 NS
Apo E3/3 % 78.060.4 72.260.5 NS
Apo E3/2 % 9.860.3 5.660.3 NS
Non-paired Student’s t-test was used to determine P values. All values are
given as the mean 6 standard deviation.measurement of serum total cholesterol, serum triglycer-
ide, serum HDL cholesterol, serum apoproteins, and the
activity of lecithin cholesterol acyltransferase (LCAT)
were described elsewhere [1]. LDL cholesterol was cal-
HDL cholesterol was slightly lower than those in nondia-culated according to Friedewald [7]. Apo E phenotyping
betic patients (Table 2). In nondiabetic uremic patients,was determined by 1-D, flat gel iso-electric focusing using
mean levels of serum apo A-1 and serum apo A-2 anda commercial kit (Jyoko, Tokyo, Japan) [8].
LCAT activities were decreased. In the diabetic uremic
patients, serum apo A-1 and serum apo A-2 and LCATStatistical analysis
activities were significantly lower (P , 0.01, P , 0.03,Means and standard deviations were calculated by
and P , 0.003, respectively). The mean concentrationconventional methods, and the statistical difference was
of apo B in diabetic patients was also lower than that ofdetermined by a nonpaired Student’s t-test.
nondiabetic patients. In all uremic patients, serum apo
C-2 was slightly decreased, and serum apo C-3 was ele-
RESULTS vated. Mean concentrations of serum apo E were de-
Clinical features of diabetic patients on 10 years creased in both uremic groups, and apo E in diabetic
of hemodialysis uremic patients was significantly lower than in nondia-
betic patients (P , 0.005).No significant differences in variables between dia-
betic and nondiabetic uremic patients were identified
Apolipoprotein E phenotyping in the diabetic uremics(Table 1). This suggests that diabetic uremic survivors
The major apo E phenotypes (E4/4, E4/3, E4/2, E3/3,as well as nondiabetic patients undergoing long-term
E3/2, and E2/2) in the healthy Japanese population arehemodialysis therapy were treated similarly. In diabetic
reported to occur at frequencies of 0.66, 16.3, 1.48, 73.2,uremic patients, a higher prevalence of macrovascular
8.4, and 0%, respectively [9]. Apo E4/2 and apo E2/2complications, including ischemic heart diseases, cere-
were not present in our uremic patients. In diabetic ure-brovascular diseases, and gangrene in lower extremities,
mic patients, the frequency of apo E3/2 was slightly de-was observed than in nondiabetic uremic patients (Table
creased, and that of apo E4/4 was slightly increased,1). These results indicate that atherosclerotic changes
although these differences did not reach a statistical sig-were more severe in diabetic uremic patients than in
nificance (Table 2). We further analyzed the apo E iso-nondiabetic uremic subjects.
form-specific effect on dyslipidemia in uremic patients.
Lipids and apolipoprotein abnormalities in diabetic In all uremic patients with apo E3/3, apo E3/4, and apo
uremic patients E4/4, serum concentrations of apo A-1, apo A-2, apo
C-2, apo E, and LCAT activity were apparently lower,The mean concentrations of serum total cholesterol,
and serum levels of apo C-3 were higher than thoseserum triglyceride, and serum HDL cholesterol in both
in uremic patients with apo E2/3 (data not shown). Ingroups were not different, although the mean concentra-
diabetic uremic patients with apo E4/3 and apo E4/4,tion of serum triglycerides in diabetic patients was
slightly higher and the mean concentration of serum mean concentrations in serum apo A-1, apo A-2, apo C-2,
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apo E, and LCAT activity were most seriously decreased malities than nondiabetic uremic patients, which could
contribute to diffuse atherosclerosis. Although the mech-(85.8, 15.5, 1.35, 2.55 mg/dl, and 16.8 U/dl, respectively).
anism linking dyslipidemia and cardiac death still needs
to be clarified, this evidence in this study supports the
DISCUSSION potential importance of dyslipidemia in patients with
diabetic uremia.Our nondiabetic uremic patients exhibited characteris-
tics of impaired lipid metabolism: decreased concentra-
Reprint requests to Dr. Takeo Goto, Department of Internal Medi-
tions in serum apo A-1, serum apo A-2, and serum apo cine, Takasago Municipal Hospital, 33-1 Kamimachi, Arai-cho, Taka-
sago 676-0015, Japan.C-2; decreased LCAT activity; and elevated levels of
serum apo C-3.
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